News
Patents granted for discovery technology in Europe, UK and India. Other territories expected to follow
Press Release: 11 November 2008
e-Therapeutics plc (AIM: ETX), the drug discovery and development company, is pleased to announce that it has been granted patent protection for its in silico drug discovery technology in Europe, the UK and India. The Company has also applied for protection in other territories, including the USA, and approvals are expected to follow shortly.
Positive Phase IIa clinical trial of the Company's oral asthma treatment
Press Release 10 October 2008
e-Therapeutics plc (AIM: ETX), the drug discovery and development company, is pleased to announce the successful conclusion of the Company’s Phase IIa clinical trial of ETX9101, a new oral treatment for asthma which has the potential to reduce exacerbation of asthma and to reduce the intake of inhaled corticosteroids and bronchodilators, thereby reducing their side-effects.
e-Therapeutics expands its global footprint in China through partnership with KeyGen Biotechnology
e-Therapeutics plc (AIM: ETX), the drug discovery and development company, is pleased to announce a new partnership with Nanjing KeyGen Biotech. Co. Limited (“Keygen”). The initial focus of the collaboration will be to combine the respective capabilities and expertise of both companies in the evaluation of specific molecules that may have a therapeutic application in oncology.
Appointment of Brad Hoy
The Company are pleased to announce the appointment of Brad Hoy as a director of the Company with immediate effect.
Bradley Richard Hoy, aged 45, is appointed as a non-executive director.
He is currently a director of Seven Hills Venture Partners Limited.
In the past five years he has also been a director of the following companies:
• Geron Biomed Limited
• Xcellsyz Limited
• Plethora Solutions Holdings plc
• Plethora Solutions Limited
• Plethora Therapeutics Limited
ETS2101 effective in in vitro studies against skin cancer and commences in vivo studies
e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, today announces the successful completion of in vitro testing of its drug candidate ETS2101 in melanoma (skin cancer), and its progression into in vivo development.
Successful completion of preclinical efficacy and resistance studies of candidate antibiotic ETX1153 against MRSA
e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, is pleased to announce the successful completion of preclinical studies of efficacy and rates of resistance of its candidate antibacterial drug compound ETX1153 against methicillin-resistant Staphylococcus aureus (MRSA), commonly referred to in lay terms as one of the hospital “superbugs”.
High potency
e-Therapeutics plc. First Day of Dealings on AIM
e-Therapeutics, the systems biology drug discovery company, today announces the first day of trading of its Ordinary Shares on the AIM market of the London Stock Exchange (“AIM”). WH Ireland is acting as Nominated Adviser and Cornhill Asset Management as Broker. The market epic code is ETX.
e-Therapeutics plc Intention to Float on AIM
e-Therapeutics, the systems biology drug discovery company, today announces its intention to proceed with a placing of its shares and to seek admission of its share capital to trading on AIM, the market owned and operated by the London Stock Exchange.
e-Therapeutics Highlights:
1. Large market opportunity
e-Science identifies new weapons in battle against hospital superbugs
Source: Research Councils UK - 24/02/07 - View Source Article
Techniques developed under the UK e-Science Programme led to the identification of the anti-MRSA drugs that received widespread publicity in the UK national media last month.
New Weapon for MRSA?
Source: Pharma Times - 18/01/2007 - View Source Article
Scientists in the UK claim they have found an effective weapon against the superbug methicillin-resistant Staphylococcus aureas, by using a computer programme designed to analyse the bacteria’s ‘weak spots’ and then matching potential compounds against them.